The estetrol-drospirenone-containing contraceptive as a drug of choice for patients with mastalgia

Mekan R. Orazov , Vasilii V. Ermakov

For citation:

Abstract

The problem of mastalgia is widespread: up to 70% of women report regular or episodic pain in the mammary gland. The role of benign breast disease in the occurrence of these complaints was noted only in 10–30% of cases, while in most women mastalgia is a manifestation of premenstrual syndrome caused by excessive water retention in the body. As a therapy for such patients, the optimal solution would be to prescribe a new combined oral contraceptive containing 15 mg of estetrol and 3 mg of drospirenone. The uniqueness of this combination in this situation lies in the pronounced antimineralocorticoid effect of drospirenone, supported by a high safety profile of estetrol, including a reduced risk of developing breast cancer compared to other combined oral contraceptive.

Key words: estetrol, drospirenone, hormonal contraception, mastalgia, mastodynia.

References

1. Scurr J, Hedger W, Morris P, Brown N. The prevalence, severity, and impact of breast pain in the general population. Breast J 2014; 20 (5): 508–13.

2. Fentiman IS. The pathophysiology and therapy of benign breast disease. In: Fauser BC, ed. Reproductive medicine: molecular, cellular and genetic fundamentals. Parthenon Publishing, 2003; p. 487–94.

3. Olawaiye A, Withiam-Leitch M, Danakas G, Kahn K. Mastalgia: a review of management. J Reprod Med 2005; 50 (12): 933–9.

4. Корженкова Г.П. Фиброзно-кистозная мастопатия: вариант нормы или болезнь? Онкогинекология. 2013; 3: 46–55. [Korzhenkova G.P. Fibrozno-kistoznaia mastopatiia: variant normy ili bolezn'? Onkoginekologiia. 2013; 3: 46–55. (in Russian).]

5. Сметник В.П., Коновалова В.Н., Леонова Н.Ю. Патофизиология и терапия доброкачественных заболеваний молочных желез: дискуссионные вопросы. Проблемы репродукции. 2009; 1: 93–9. [Smetnik V.P., Konovalova V.N., Leonova N.Iu. Patofiziologiia i terapiia dobrokachestvennykh zabolevanii molochnykh zhelez: diskussionnye voprosy. Problemy reproduktsii. 2009; 1: 93–9 (in Russian).]

6. Rapkin AJ, Winer SA. Drospirenone: a novel progestin. Expert Opin Pharmacother 2007; 8 (7): 989–99. DOI: 10.1517/14656566.8.7.989; PMID: 17472544.

7. Andreeva EN, Grigoryan OR, Korzhenkova GP. External application of gestagens for the treatment of mastalgia due to treatment with combined oral contraceptives in women with a fibrocystic breast changes. Probl Reprod 2016; 22: 86. DOI: 10.17116/repro201622486-94

8. Foidart JM, Wuttke W, Bouw GM et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5 (2): 124– 34. DOI: 10.1080/13625180008500387

9. Chen MJ, Jensen JT, Kaunitz AM et al. Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials. Contraception 2022; 116: 44–50. DOI: 10.1016/j.contraception.2022.10.004; PMID: 36257374.

10. Frobenius W. “The rabbits are prepared…” – The development of ethinylestradiol and ethinyltestosterone. J Reproduktionsmed Endokrinol 2011; 8 (Suppl. 1): 32–57.

11. Lidegaard O, Lokkegaard E, Svendsen AL et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.

12. Lidegaard O, Nielsen LH, Skovlund CW et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343: d6423.

13. Morch LS, Skovlund CW, Hannaford PC et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 2017; 377 (23): 2228–39.

14. Chlebowski RT, Hendrix SL, Langer RD et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women’s health initiative randomized trial. JAMA 2003; 289 (24): 3243–53.

15. Manson JE, Kaunitz AM. Menopause management – getting clinical care back on track. N Engl J Med 2016; 374 (9): 803–6.

16. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the qResearch and CPRD databases. BMJ 2019; 364: k4810.

17. Klipping C, Duijkers I, Mawet M et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception 2021; 103 (4): 213–21. DOI: 10.1016/j.contraception.2021.01.001; PMID: 33428907.

18. Hammond GL, Hogeveen KN, Visser M et al. Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells. Climacteric 2008; (Suppl. 11): 41–6.

19. Siiteri PK, Murai JT, Hammond GL et al. The serum transport of steroid hormones. Recent Prog Horm Res 1982; 38: 457–510.

20. Collaborative Group on Hormonal Factors in Breast Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713–27. DOI: 10.1016/S0140-6736(96)90806-5

21. Gerard C, Mestdagt M, Tskitishvili E et al. Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms. Oncotarget 2015; 6 (19): 17621–36.

22. Gerard C, Blacher S, Communal L et al. Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation. J Endocrinol 2015; 224 (1): 85–95.

23. Coelingh Bennink HJT, Singer C, Simoncini T et al. Estetrol, a pregnancy-specific human steroid, prevents and suppresses mammary tumor growth in a rat model. Climacteric 2008; 11 (Suppl. 1): 29.

24. Gallez A, Blacher S, Maquoi E et al. Estetrol combined to progesterone for menopause or contraception indication is neutral on breast cancer. Cancers (Basel) 2021; 13: 2486.

25. Singer CF, Bennink HJ, Natter C et al. Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. Carcinogenesis 2014; 35 (11): 2447–51.

26. Schmidt M, Lenhard H, Hoenig A et al. Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer. J Cancer Res Clin Oncol 2021; 147 (6): 1833–42.

For citation:Orazov M.R., Ermakov V.V. The estetrol-drospirenone-containing contraceptive as a drug of choice for patients with mastalgia. Clinical review for general practice. 2023; 4 (3): 56–59. DOI: 10.47407/kr2023.4.3.00224

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice